RecruitingPhase 3NCT04293562
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Sponsor: Children's Oncology Group
Bangor, ME · Scarborough, ME · +184 more sites